Psilocybin for Major Depressive Disorder: PSIL301

RECRUITMENT FOR STUDY

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between groups in change in depressive symptoms from Baseline to Day 43 post-dose, and to characterize the durability of initial treatment effect and subsequent response to optional Psilocybin 25 mg re-administration(s) during the 1-year Follow-up Period. This study is sponsored by Usona Institute.

To inquire about participation in the PSILO301 Study, apply below:

For more information about the study: https://clinicaltrials.gov/study/NCT06308653?term=USONA&rank=2